Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

8.29
-0.7000-7.79%
Post-market: 8.28-0.0100-0.12%19:57 EDT
Volume:27.81M
Turnover:238.14M
Market Cap:3.76B
PE:-11.75
High:9.30
Open:9.08
Low:8.15
Close:8.99
52wk High:9.36
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.25
T/O Rate:7.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:5.10
PE(LYR):-7.58

Loading ...

Iovance director Wendy Yarno to retire from board in June 2026

Reuters
·
Mar 21

Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan

Simply Wall St.
·
Mar 11

A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum

Simply Wall St.
·
Mar 09

Iovance Biotherapeutics call volume above normal and directionally bullish

TIPRANKS
·
Mar 07

What's Going On With Iovance Biotherapeutics Stock On Friday?

Benzinga_recent_news
·
Mar 07

UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating

MT Newswires Live
·
Mar 05

Iovance Biotherapeutics Is Maintained at Neutral by UBS

Dow Jones
·
Mar 05

Iovance Biotherapeutics Inc : UBS Raises Target Price to $4 From $2

THOMSON REUTERS
·
Mar 05

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

TIPRANKS
·
Mar 05

Iovance Biotherapeutics Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Mar 03

Iovance Biotherapeutics to Present at TD Cowen Annual Healthcare Conference and Barclays Global Healthcare Conference

Reuters
·
Feb 26

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Feb 26

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 26

Stock Track | Iovance Biotherapeutics Soars 12.04% Intraday on Multiple Analyst Upgrades and Target Price Increases

Stock Track
·
Feb 25

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

TIPRANKS
·
Feb 25

Iovance Biotherapeutics Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Feb 25

Chardan Lowers Price Target on Iovance Biotherapeutics to $16 From $17, Keeps Buy Rating

MT Newswires Live
·
Feb 25

Stock Track | Iovance Biotherapeutics Soars 5.29% in Pre-market on Barclays' Buy Rating

Stock Track
·
Feb 25

Barclays Remains a Buy on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Feb 25

NASD Most Active Issues

Dow Jones
·
Feb 25